A carregar...
Publicação
Estudo dos fatores preditivos de resposta patológica completa à quimioterapia neoadjuvante em neoplasias da mama do tipo luminal B
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 2.7 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Introdução. O cancro da mama é a doença oncológica mais frequente no sexo feminino. No seu tratamento, a quimioterapia neoadjuvante tem sido uma valiosa arma que permite aumentar a possibilidade de cirurgia conservadora e atingir uma resposta patológica completa. Esta pode significar um melhor prognóstico nos tumores luminais B/HER2-negativos face àqueles que não a atingiram. De modo a identificar os doentes que poderão beneficiar mais da utilização de quimioterapia em contexto neoadjuvante, é necessário identificar fatores preditivos de resposta à mesma, havendo atualmente alguns já utilizados na prática clínica.
Objetivos. Compreender a influência dos valores de: ER+, PR+, Ki67 e grau histológico, na resposta patológica completa à quimioterapia neoadjuvante nos tumores luminais B HER negativos; compreender a influência dos mesmos na resposta (parcial + completa) à quimioterapia neoadjuvante nos tumores luminais B.
Metodologia. Para o cumprimento dos objetivos propostos, foi feita a análise de uma base de dados com a informação clínica de 87 doentes do sexo feminino, acompanhadas na consulta de oncologia do hospital de Santa Maria e com diagnóstico de cancro da mama do tipo luminal B entre os anos de 2014 e 2018. A base de dados foi fornecida pelo Doutor Luís Costa e a análise estatística foi realizada com recurso ao programa SPSS.
Resultados Esperados. Tendo em conta a pesquisa bibliográfica, espera-se observar associação entre valores mais elevados de Ki67 e melhor resposta à quimioterapia neoadjuvante.
Introduction. Breast cancer is the most common cancer in women. Regarding its treatment, neoadjuvant chemotherapy has been a valuable weapon that increases the possibility of having a conservative surgery and achieving a pathologic complete response, which may lead to a better prognosis in luminal B / HER2-negative tumors compared to those who did not reach it. In order to identify patients who may benefit most from the use of chemotherapy in a neoadjuvant setting, it is necessary to identify predictive factors of response to it. In today’s clinical practice there are a few factors already being used. Goals. Understand the influence of the values of: ER +, PR +, Ki67 and histological grade, in the pathologic complete response to neoadjuvant chemotherapy in luminal B HER2-negative tumors; understand their influence on the response (partial + complete) to neoadjuvant chemotherapy in luminal B tumors. Methodology. In order to fulfill the mentioned goals, a database, which had the clinical information of 87 female patients diagnosed with luminal type B breast cancer among the years 2014 and 2018 that were under the care of the oncology department at Santa Maria Hospital, was analyzed. The database was provided by Doctor Luís Costa and the statistical analysis was performed using the SPSS program. Expected results. Taking into account the literature research, it is expected an association between higher Ki67 values and better response to neoadjuvant chemotherapy.
Introduction. Breast cancer is the most common cancer in women. Regarding its treatment, neoadjuvant chemotherapy has been a valuable weapon that increases the possibility of having a conservative surgery and achieving a pathologic complete response, which may lead to a better prognosis in luminal B / HER2-negative tumors compared to those who did not reach it. In order to identify patients who may benefit most from the use of chemotherapy in a neoadjuvant setting, it is necessary to identify predictive factors of response to it. In today’s clinical practice there are a few factors already being used. Goals. Understand the influence of the values of: ER +, PR +, Ki67 and histological grade, in the pathologic complete response to neoadjuvant chemotherapy in luminal B HER2-negative tumors; understand their influence on the response (partial + complete) to neoadjuvant chemotherapy in luminal B tumors. Methodology. In order to fulfill the mentioned goals, a database, which had the clinical information of 87 female patients diagnosed with luminal type B breast cancer among the years 2014 and 2018 that were under the care of the oncology department at Santa Maria Hospital, was analyzed. The database was provided by Doctor Luís Costa and the statistical analysis was performed using the SPSS program. Expected results. Taking into account the literature research, it is expected an association between higher Ki67 values and better response to neoadjuvant chemotherapy.
Descrição
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2021
Palavras-chave
Resposta patológica completa Fatores preditivos de resposta Cancro da mama precoce Oncologia